Research Article

Macrocycles as Promising Selective Drug Candidates with special reference to Inhibitors and Receptors

Subhash, Pinki and Ashu Chaudhary*

Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India

Abstract

Macrocyclic molecules are typically found in bioactive natural items and pharmaceutical atoms. Up until this point, countless macrocyclic natural items have been isolated and synthesized. The advancement of macrocycles is usually measured as a noteworthy and testing step in the blend of macrocyclic natural products. Over the span of the latest an exceptionally extended period of time, different undertakings have been endeavoured toward the union of complex normally happening macrocycles and incredible advances have been made to push the field of total synthesis. The essential objective of the review is to condense presently utilized macrocyclic drugs, feature the remedial capability of this underexplored drug class. The current advances in the field of macrocyclic science, especially, having the option to prepare metallomacrocycles have enabled individuals to devise new strategies for the course of action of antimicrobial and against tumor specialists. This article lights up utilization of macrocyclic structures in the field of remedial science.

Keywords: Synthetic macrocycle, Natural product, Macrocyclic Drugs, Antimicrobial, Anti-tumor, Macrocyclization, Enzyme Inhibitors

***Correspondence**

Author: Ashu Chaudhary

Email: ashuchaudhary21@gmail.com



Introduction

Macrocycles involve an extraordinary fragment of synthetic space. In the previous decade, their compound decent variety extended significantly, bolstered by propels in bioinformatics and synthetic methodology. As an outcome, this basic sort has now been effectively tried on most natural objective classes. The objective of this article is to place into point of view the current applications, openings, and difficulties related with manufactured macrocycles in tranquilize discovery [1].

Historically, macrocyclic drug candidates have originated primarily from two sources. The first, natural products, provided unique drugs such as erythromycin, rapamycin, vancomycin, cyclosporin, and epothilone. Excellent reviews are dedicated to this class and how it inspired further synthetic and medicinal chemistry efforts; thus, it will not be covered here [1-3]. From a molecular evolution standpoint, the medicinal chemistry of macrocyclic natural products usually involved direct use as a therapeutic agent or functionalization of the natural product scaffold by hemi synthesis. [4, 5]

The second traditional source of macrocycles stems from peptides, some of which are natural products and, hence, also belong to the first category. Macrocyclization was recognized early in peptide chemistry as an efficient way to restrict peptide conformation, reduce polarity, increase proteolytic stability, and consequently improve draggability. Chemists accessed macrocyclic peptides with different geometries (head to tail, side chain to side chain, head to side chain), including the incorporation of nonpeptidic groups [6-8]. Compelling examples of macrocyclic scaffolding of peptides include the works on somatostatins, melanocortins, and integrins, among others. [9-12] Macrocyclic peptides generated several drugs from synthetic or natural sources, including octreotide, cyclosporine, eptifibatide, and caspofungin.

Medicinal chemistry relies strategically on robust synthetic methods capable of producing an acceptable chemical diversity to adequately interrogate the chemical interplanetary of a biological target. Macrocycles are often perceived as difficult to synthesize and hence deterred many medicinal chemists because of the lack of versatile synthetic platforms. [13-15]

Numerous researchers have talked about the job that macrocycles can play in medicinal chemistry, specifically looking past the built-up significance of natural product macrocycles in medicate revelation [16]. The utilization of medication like macrocycles is developing as an energizing zone of medicinal chemistry; with a few ongoing models featuring the great changes in biological and physicochemical properties that macrocyclization can bear. Despite the fact that the structural unpredictability and synthetic obstinacy limit their pharmaceutical application, macrocycles have wide applications in drug discovery and advancement; and various natural macrocyclic compounds present excellent remedial potential and unmatched biological activities [17]. Natural product macrocycles and their synthetic subsidiaries have for quite some time been clinically valuable and consideration is presently being centred on the more extensive utilization of macrocyclic platforms in therapeutic chemistry in the quest for new medications for progressively testing targets [18]. Verifiably, macrocyclic molecules speak to an effectively archived sedate class in the facility. It has been contended that macrocyclic structures are underexploited in tranquilize revelation, and introduced various classes of natural product macrocycles and their applications to feature the appropriateness of the basic class for further development [19]. Medicinal inorganic chemistry offers extra open doors for the structure of helpful operators not available to organic compounds. The wide scope of coordination numbers and geometries, accessible redox states, thermodynamic and kinetic qualities, and intrinsic properties of the cationic metal ion and ligand itself offer the therapeutic physicist an enormous assortment of reactivity's to be abused [20].

Synthetic Macrocycles in Drug Discovery

Macrocycles have been utilized effectively on most pharmaceutical objective classes. The biggest number of reports originates from the protease field, a result of the improvement of rigidified peptide ligand impersonates. The third objective class, and maybe the one having the best development potential given the significant level of intrigue it pulled in the previous scarcely any years, is the disturbance of protein-protein associations, which misuses the remarkable properties of the macrocyclic topology. Instead of checking on widely every macrocycle on each target class, we will concentrate on chosen models and put in context their qualities, including points of interest and impediments over acyclic analogs when accessible.

Macrocyclic Enzyme Inhibitors

Numerous projects planned for distinguishing chemical inhibitors began from X-ray structures of the compound's substrate or hydrolysis item in complex with the enzyme. In the protease field, macrocyclization end up being an effective method to predisposition the compliance of a lead compound toward a bound adaptation while at the same time expanding proteolytic soundness and decreasing polarity [21, 22].

A few X-ray structures uncovered that proteases all around perceive their ligands in the β-strand adaptation, biasing the balanced plan of inhibitors toward this specific optional structure [23, 24]. This method of cooperation is additionally seen in a few normally happening macrocyclic protease inhibitors, for example, the ACE inhibitor 1 (K-13) and aminopeptidase B inhibitor 2 [25, 26] which motivated the structure of a few mixes including the HIV protease inhibitor 3 (**Figure 1**) [27].



Figure 1 Macrocyclic biphenyl ether scaffold.

The different kinds of β-strand impersonates consolidated in macrocycles have been checked on by Glenn and Fairlie [28]. Macrocyclization was perceived during the 1980s as an efficient approach to confine peptidic change state imitates into adaptations intently looking like those found in compound inhibitor edifices [22]. Spearheading works from a few gatherings built up the necessary highlights of macrocyclic β-strand emulates by means of the utilization of compelled side chain to spine cyclization for aseptic and serine proteases [27,29]. This class of macrocyclic inhibitors was utilized widely to check the agreeable idea of catalyst inhibitor official (instigated fit), [30] a common acknowledgment that can have short-or significant distance conformational repercussions and can obstruct the structure of particular inhibitors [31].

Neutral Endopeptidase 24.11 inhibitors

McPherson et al. revealed macrocyclic inhibitor 4 (**Figure 2**) as an intense inhibitor of neutral endopeptidase (NEP) 24.11.[32] NEP is a zinc metalloprotease liable for the first hydrolytic venture of atrial natriuretic factor (ANF), a hormonal objective for cardiovascular clutters because of its contribution in natriuresis, diuresis, and bringing down of circulatory strain. Plan of the macrocycle was roused by the X-ray structure of a transition state inhibitor of thermolysin, which uncovered two coterminous hydrophobic pockets [33]. Macrocycle 4 was acquired after intensive improvement of the exocyclic amide substituent. It showed sub nanomolar hindrance of NEP 24.11. Its twofold prodrug 5 (CGS-25155) gave a supported diminishing in mean blood pressure of hypertensive rodents after organization at 30 mpk, with an impact enduring up to 6 h. 4, 5, and analogs were acquired by two sequential ring developments from cyclooctanone.

Ksander et al. announced two comparative arrangements of NEP inhibitors. The main, in light of ortho-subbed macrocycle 6, showed intense NEP restraint with a high selectivity for angiotensin-changing over chemical (ACE) [34, 35]. PC helped configuration prompted meta-subbed simple 7, which had a double NEP/ACE inhibitory profile. This is an excellent example of how the balance of conformational restriction and flexibility of similar macrocyclic scaffolds can be exploited to fine-tune selectivity.



Figure 2 Macrocyclic NEP inhibitors

HIV Protease inhibitors

The HIV protease is a clinically approved objective for the administration of HIV. Likewise, with other aspartyl proteases, its restraint was effectively moved toward utilizing the hydroxyethyl amino transition state impersonates. Propelled by the structure of natural products 1 and 2, Janetka et al. revealed biphenyl ether 3 (Ki = 15 nM,) as an early inhibitor of HIV protease [27]. Macrocyclization forced a conformationally limited stretched out β-strand structure to its peptidic divide. The para-meta substitution design on the diphenyl ether was 60-overlay more powerful than the meta-para isomer, recommending a superior attack of the side chains in the protease dynamic site. Macrocyclization was performed utilizing S_NAr by a ruthenium π-aryl complex [36]. Extra inhibitors having endocyclic phenoxy ether were additionally revealed [37]. The crystal structure of the HIV protease in complex with non-cyclic hydroxy ethylene isostere inhibitor 8 [38]. prompted the plan of a few macrocyclic inhibitors, exemplified by 9 (Ki = 12 nM, **Figure 3**) [39]. These 15-to 17-membered macrocycles all have the β-strand adaptation. Inhibitors 8 and 9 embrace comparable restricting modes, with the macrocyclic structure forcing a difference of 25° in the χ1 dihedral point of the endocyclic aromatic ring in 9. Like their non-cyclic congeners, inhibitor 10 [40] and analogs were dependent upon the known exchanging stereoisomer inclination of HIV protease inhibitors, [41] forced by the difference in hydrophobicity of the P1 build-up. Substitution of the Asn moiety of 10 by Val diminished official by around 1 request for greatness, because of the loss of a significant H-bond.



Figure 3 Macrocyclic HIV protease inhibitors

Based on a similar beginning inhibitor (8), cyclization was explored on the C-terminal finish of the peptide, giving analogs, for example, 11 bearing a positive ammonium gathering. Contrasted with past analogs showing collaborations of both hydroxyl group with Asp^{25} and Asp^{125} in the synergist site, the hydroxyl gathering of 11 interfaced with Asp^{125} while its ammonium group communicated with Asp^{25} and the macrocycle had an additional atom. This change was suited by an interpretation of about 1.5 Å in the precious crystal structure. With both N-and C-terminal parts of the bargains manageable to macrocyclization (10 and 11), it was enticing to decide if the chemical's dynamic site could at the same time house a macrocyclic substructure at the two parts of the bargains. The Ki estimation of 3 nM for inhibitor 12 decidedly responded to this inquiry; in any case, the nearness of the two macrocycles didn't get a synergistic increment restricting [42] Structurally, the coupling method of the C-terminal macrocyclic inhibitor 11 was forced, with hydroxyl and ammonium groups all the while interfacing with Asp^{125} and Asp^{25}, individually. This class of macrocycles mirrors tripeptide β-strand structures in water, a theme generally perceived by proteases [24, 43] Moreover, these macrocycles embraced an inflexible topology (huge 3JNH-CHR of 9-10 Hz) with no intramolecular hydrogen bond related with ordinary turn structures watched (all amide bond substance shifts were temperature subordinate, with $\Delta\delta/\Delta T$ estimations of 7-12 ppb/deg). This mix of auxiliary highlights made a perfect format for proteases. Bis-macrocycle 12 and its analogs were additionally utilized as tests to additionally clarify the catalytic mechanism [44].

The X-ray structure of profoundly powerful HIV inhibitor 13 (FDA-affirmed darunavir, Figure 3) and its simple 14 in complex with the HIV protease demonstrated a vicinity between the P1 and P2 spaces. Based on this perception, Ghosh et al. [45] fused the left-hand side of the particle in a progression of 13-to 15-membered macrocycles. Darunavir was at first intended to (1) repress HIV protease and (2) forestall the key advance of HIV protease dimerization while limiting cooperations with the variable side chains of the protease and amplifying associations with the less factor protease spine. The most powerful simple of the arrangement, 15, showed sub nanomolar intensity on the detached compound. Ring size or the nearness of endocyclic unsaturation had insignificant effect on intensity. Similarly, open-chain structures likewise showed potencies in the low nanomolar level. So as to fill the $S1^0$ and $S2^0$ subsites, the creators researched flexible macrocyclic analogs holding polar spine collaborations while boosting van der Waals connections [46]. Subsequently, 13-membered macrocycles 16 showed choice inhibitory movement in vitro and in cellulo. To be noted, 10-to 15-membered macrocycles were integrated with potencies fluctuating basically inside 1 log unit; the 10-and 13-membered analogs demonstrated the best potencies and unsaturation by and large demonstrated beneficial. Conversely, acyclic derivatives had Ki somewhere in the range of 0.1 and 17 nM and in cellulo IC50 over 300 nM, stressing the benefits of macrocyclization on cell penetration.

Specifically noteworthy, these macrocycles had fantastic movement profiles against a few multidrug-safe clinical secludes, an effect credited to the mix of (1) direct authoritative to the less factor protease spine space and (2) inhabitance of a hydrophobic pocket in the S1-S2 subsites. 16 had more van der Waals cooperations with the HIV protease than 13 (Val84 and Ile82) [47]. All in all, these macrocycles, just as different individuals from a similar family, [48] were integrated utilizing ring closing metathesis (RCM). Comparative macrocyclic scaffolds were effectively applied to create inhibitors of other pharmaceutically pertinent proteases, including calpain, [49]. plasmepsins, [50] peptide deformylase, grid metalloproteases, [51] and TNF-R changing over catalyst (TACE).

HCV NS3 Protease Inhibitors

The (HCV) NS3 protease is a fundamental catalyst in the replication of the virus and a clinically approved objective for the treatment of hepatitis C. The most important and exceptional HCV protease inhibitors, 17 (telaprevir, **Figure 4**) and 18 (boceprevir, SCH503034), are as of now in stage III clinical advancement [52]. Both are acyclic covalent transition state impersonates highlighting a reversible snare for the catalytic Ser^{139} buildup on their C end. Basically, the identity of this serine protease is the nearness of a shallow, dissolvable uncovered parted as the S4-S1 substrate binding region, which demonstrated testing to focus with small molecules [53]. structural analysis of the objective uncovered that the S3-S1, S4-S2, and S3-S2 restricting pockets were in nearness, giving the method of reasoning to a few methods of macrocyclization.

Thrombin Inhibitors

Inhibitors of the thrombin have a very much perceived potential for the treatment of profound vein thrombosis, pneumonic embolism, and thromboembolic stroke. Assessment of X-ray structures of thrombin complex with intense acyclic inhibitor 35 (**Figure 5**) [54]. Uncovered the closeness of the P3 and P1 groups, driving Nantermet et al. to confine conformational opportunity of the atom by means of macrocyclization [55]. Macrocycles 36 didn't have improved intensity; in any case, it held great selectivity (>2000-crease) versus trypsin and tissue plasminogen activator (tPa). Supplanting of the proline moiety with a pyrazinone prompted inhibitor 37 having extraordinary

power (Ki = 0.09 nM) and selectivity against trypsin and tPa (23000-and 7100-overlay, individually). The secondary amine moiety of 37 was urgent for collaboration with Glu[192] of thrombin, a buildup supplanted by Gln in both trypsin and tPa, prompting the expanded power and selectivity watched. To be noticed, these macrocycles are very unique in relation to the macrocyclic common item cyclotheonamide A (38), which is additionally an inhibitor of thrombin [56].



Figure 4 Macrocyclic covalent reversible HCV NS3 protease inhibitors

G Protein-coupled Receptors

These are the biggest class of pharmaceutical targets speaking to 30-40% of current showcased drugs. The plan of GPCR ligands doesn't profit by a similar level of structural support contrasted with proteases, since just five GPCR X-ray structures have been accounted for to date instead of a few thousand for proteases. Commonly, molecular modeling of GPCRs is finished by homology to the bunch of receptors that have respected crystallization. Confinement on the cell surface is a favourable position for GPCRs as far as target openness contrasted with intracellular targets, for example, numerous proteases or protein-protein interactions. This distinction is huge, since atoms focused on GPCRs don't need to enter cells to arrive at their objectives. Macrocyclic peptides have developed as a class of "privileged structures" for GPCRs [57-59]. Despite the fact that they won't be portrayed in detail right now, structures regularly can give a sensible beginning stage to nonpeptidic ligand design.

CXCR4 Antagonistists

Focusing on this mechanism to forestall cellular entry of the virus is another treatment choice, supplementing prior methodologies dependent on the restraint of intracellular viral enzymes. While the CCR5 receptor is commonly

connected with early periods of contamination by HIV and is utilized by M-tropic viruses, the CXCR4 is commonly utilized by the more pathogenic T-type viruses. The first macrocycles to be distinguished as CXCR4 inhibitors were bis-tetraazamacrocycles (bicyclams, conventional structure 39, **Figure 6**) [60]. The class had no impact on either the CD4 receptor or gp120 glycoprotein, and at the hour of its disclosure its objective was obscure. It was later exhibited that 40 forestalls cooperation of the CXCR4 receptor with its related ligand, the CXCL12 chemokine. The most powerful macrocycle of this dimeric arrangement hindered HIV-1 replication at a convergence of 0.005 μg/mL, yet showed no cytotoxicity up to 500 μg/mL.



Figure 5 Macrocyclic thrombin inhibitors



Figure 6 Macrocyclic CXCR4 antagonists.

The aryl linker was useful for biological activity [61]. Early QSAR investigation of a progression of analogs showed that both macrocycles were vital for high antiviral movement and that ring size, separation between ring centroids, and absence of nitrogen substitution were significant parameters for action [62]. 40 needed oral

bioavailability and was managed iv, confining its relevance when numerous anti-HIV drugs are controlled orally. 40 was affirmed as of late as another HIV treatment, yet additionally has potential for fiery illnesses, malignancy, and undifferentiated cell preparation [63, 64]. The quest for intense and orally bioavailable CXCR4 opponents is progressing. As of late, simple 41 (AMD3465) having a solitary cyclam moiety was accounted for to have comparative movement to 40 in vitro [65]. Extra reports by Bridger et al. completely explained the significance of having one versus two rings and ring size, just as the quantity of nitrogen atoms in each ring [66]

Motilin Antagonists

Motilin is an amino acid peptide hormone that connects through a GPCR. Pulsatile arrival of motilin compares to stage 3 of the migrating motor complex a peristaltic contractile movement beginning from the stomach, and voyaging aborally and liable for gut motility in the fasted state. A few agonists of the motilin receptor, practically all with macrolide core structures got from erythromycin, have arrived at clinical turn of events.

Marsault et al. revealed a novel class of motilin enemies, following HTS of 10 000 macrocycles from a decent variety arranged library of macrocyclic peptidomimetic [67] From this HTS crusade, motilin opponent 42 (**Figure 7**) was distinguished, having a significant level of power from which to start a program (IC_{50} = 137 nM). Lead enhancement considers prompted numerous analogs with low nano-molar strength, including analogs having novel unnatural fundamental amino acids (nonexclusive structure 43, IC_{50} = 1-20 nM) [68]. The non-attendance of receptor collaboration with the relating straight ligand demonstrated that macrocyclization expanded fondness by in any event 4 sets of extent. Analogs were incorporated utilizing two strong stage engineered approaches, utilizing macrolactamization or RCM, both related to a cyclative discharge step key to the conveyance of unrefined items with adequate immaculateness.



Figure 7 Macrocyclic motilin antagonists.

Ring size, chemical nature of the four parts, and stereochemistry were methodically shifted to affirm that the DDL stereochemistry for the amino acid segments was obviously liked. Creature concentrates in dogs exhibited that lead JTZ2002 had the option to obstruct the precipitously happening MMC and diminish fundic tone and that restraint of the motilin receptor decreased both fasted and postprandial mechanical action, properties that might be helpful in the advancement of a medication for useful dyspepsia or the bad tempered inside disorder [69]. Further, the most exceptional up-and-comer of this macrocyclic arrangement, TZP-201 de-monstrated adequacy in a dog model of chemotherapy-instigated diarrhea provoked by irinotecan. TZP-201 end up being better than ebb and flow medicines, loperamide and octreotide, right now.

Protein – Protein Interaction Inhibitors

Undoubtedly, the communicating deposits in protein-protein interactions (PPI) problem areas normally spread a surface area of a few hundred [70,71] Macrocycles spread topologically characterized surface area with limited conformational flexibility and henceforth seem perfect to fill in as potential imitates for cooperation at such problem areas. Moreover, macrocyclization is a proficient method for expanding cell entrance by means of the decline in polarity of peptidic leads as plentifully exhibited with proteases. Basically, macrocycles appear to have the qualities required for a favoured structure for the adjustment of PPI. A convincing case of the specific pertinence of the macrocyclic structure right now is found in the different macrocyclic natural product and analogs thereof that show restraint of Hsp90, which have been looked into and won't be secured explicitly here.

Grb SH2 Modulators

The Grb2 group of SH2 areas is engaged with the motioning of ErbB-2 and is connected to a several breast cancers [72]. Phosphorylated tyrosine (pY) deposits pre-sent on the agreement succession pY-XNX show high affinities for SH2 spaces, with particularity arranged by the buildups flanking these critical buildups. Assessment of the 2.1 Å goals precious crystal structure of the Grb2 SH2 area in complex with the peptide KPF-pY-VNV uncovered the nearness of a β-turn adaptation in the ligand, bringing the pY and Asn binding pockets into vicinity [73].Based on lead arrangement 44 (**Figure 8**) preorganized in a β-turn conformation, the generation of macrocycle 46 (IC_{50} = 20 nM) end up being a reasonable decision, improving binding strength by 2 sets of extent contrasted with simple 45 missing the pY R-amino group [74]. In entire cell examines, be that as it may, the intensity of macrocycle 46 was more vulnerable than its acyclic congeners, a distinction reliably saw in a human breast cancer growth cell development measure. Investigation of the solution structure of the Grb SH2 space complexed with macrocycle 46 utilizing a perdeuterated protein area prompted flawlessly intense inhibitor 47 bearing an acidic group in lieu of the acetamido side chain of pY and an electron-rich 5-methylindole group [75]. Critically, this macrocycle was adequate in entire cell examines, showing hearty antiproliferative properties in ErbB2-subordinate MDA-MB-453 bosom malignant growth cells. The explicitness of the watched impact was con-solidified by the absence of antiproliferative properties in MDA-MB-231 breast cancer cells that are autonomous of the Erb-B2 development pathway. Ensuing advancement included the substitution of the phosphonic acid by a malonate, which docks into the pY restricting pocket [76,77]. Elective macrocyclic peptidic frameworks without the pY residue were as of late revealed also.



Figure 8 Macrocyclic Grb SH2 domain inhibitors and sonic hedgehog inhibitors

Neurotrophin Mimics

Based on the macrocyclic peptidomimetic scaffold Maliartchouk et al. detailed macrocycle 50 (**Figure 9** as an agonist of the TrkA receptor, which had high liking for the neurotrophin nerve growth factor (NGF) [78]. 50 was segregated from a small library of 60 macrocyclic peptidomimetics intended to imitate β-turn problem areas. Adroitly, 50 speaks to an alluring option in contrast to the remedial utilization of NGF. It specifically and fixation conditionally blocked mAb 5C3-TrkA cooperation's with IC_{50} = 4 μM and furthermore potentiated TrkA-subordinate NGF-animated DRG neuronal endurance. This impact was not seen within the sight of epidermal growth factor (EGF), proposing particularity for NGF. Hence, Pattarawarapan et al. announced macrocycle 51 dependents on a similar platform [79]. The impact was explicit for TrkC-communicating cells and was abolished in TrkA-communicating cells. Basically, macrocycles 50 and 51 exhibit the capacity of small molecules macrocycles to mirror enormous protein accomplices [80].



50
TrkA - dependent NGF mimic



51
TrKC - dependent NT3 mimic

Figure 9 Macrocyclic NGF and NT- 3 mimics

Conclusion

Macrocycles have been misused on most classes of pharmaceutical targets. In the case of starting from natural products or peptides, numerous medications having a place with the macrocycle chemotype are at present utilized in treatment. Macrocyclization additionally diminished overall polarity, improved cellular penetration and expanded bioavailability. Without a doubt, a few of the above models made molecules with great to amazing oral bio availabilities.

Acknowledgement

The authors Mr. Subhash and Pinki wish to express gratitude to the University Grants Commission (UGC) (Ref. No.- 92(CSIR-UGC NET DEC. 2018) and Council of Scientific and Industrial Research (CSIR) (Ref. No.- 16/06/2019(i) EU-V.), New Delhi, India New Delhi for financial assistance in the form of JRF.

Reference

[1] E. M. Driggers, S. P. Hale, J. Lee, N. K. 2008.Terrett, Nat. Rev. Drug Discovery, 7, 608.
[2] L. A. Wessjohann, E. Ruijter, D. Garcia-Rivera, W. Brandt. 2005. Mol. Diversity 9, 171.
[3] M. S. Butle. 2005. Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. 22, 162.
[4] A. Gradillas, J. Perez-Castells. 2006. Macrocyclization by ring-closing metathesis in the total synthesis of natural products: reaction conditions and limitations. Angew. Chem., Int. Ed. 45, 6086.
[5] A. Parenty, X. Moreau, J. M. Campagne. 2006. Macrolactonizations in the total synthesis of natural products. Chem. Rev. 106, 911.
[6] C. Adessi, C. Soto. 2002. converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963.
[7] C. Gilon, D. Halle, M. Chorev, Z. Selinger, G. Byk. 1991. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers 31, 745.
[8] R. P. McGeary, D. P. Fairlie. 1998. Macrocyclic peptidomimetics: potential for drug development. Curr. Opin. Drug Discovery Dev. 1, 208.
[9] S. Jackson, W. DeGrado, A. Dwivedi, A. Parthasarathy, A. Higley, J. Krywko, A. Rockwell, J. Markwalder, G. Wells. 1994. Template- constrained cyclic peptides: design of high affinity ligands for GPIIb/ GPIIIa. J. Am. Chem. Soc. 116, 3220.
[10] D. Gottschling, J. Boer, A. Schuster, B. Holzmann, H. Kessler. 2002. Combinatorial and rational strategies to develop nonpeptidic alpha4- beta7-integrin antagonists from cyclic peptides. Angew. Chem., Int. Ed. 41, 3007.
[11] M. Pawlikowski, G. Melen-Mucha. 2004. Somatostatin analogs: from new molecules to new applications. Curr. Opin. Pharmacol. 4, 608.
[12] P. Grieco, M. Cai, L. Liu, A. Mayorov, K. Chandler, D. Trivedi, G. Lin, P, Campiglia, E. Novellino, V.J. Hruby. 2008. Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. J. Med. Chem. 51, 2701.
[13] J. S. Bradshaw, K. E Krakowiak, and R. M. Izatt. 1993. Aza- Crown Macrocycles, J. Wiley & Sons, New York,

83.
[14] P. Hodge, H. M. Colquhoun, and D. Williams. 1998. Chem. Ind. 162.
[15] S. V. Shevchuk, J. M. Davis, and J. L. Sessler. 2001. Tetrahedron Lett, 42, 2447.
[16] A.K. Oyelere. 2010. Macrocycles in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 10, 1359–1360.
[17] E.M. Driggers, S.P. Hale, J. Lee, and N.K. Terrett. 2008. The exploration of macrocycles for drug discovery an underexploited structural class. Nat. Rev. Drug Discov. 7, 608–624.
[18] J. Mallinson, and I. Collins. 2012. Macrocycles in new drug discovery. Future Med. Chem. 4, 1409–1438.
[19] L. Sandegren. 2014. Selection of antibiotic resistance at very low antibiotic concentrations. Upsala J. Med. Sci. 119, 103−107.
[20] C. Santini, M. Pellei, V. Gandin, M. Porchia, F. Tisato, and C. Marzano. 2014. Advances in copper complexes as anticancer agents. Chem. Rev. 114, 815−862.
[21] C. Adessi, C. Soto. 2002. converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963.
[22] C. Gilon, D. Halle, M. Chorev, Z. Selinger, G. Byk. 1991. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers 31, 745.
[23] J. D. Tyndall, J. T. Nall, D. P. Fairlie. 2005. Proteases universally recognize beta strands in their active sites. Chem. Rev. 105, 973.
[24] P. K. Madala, J. D. Tyndall, T. Nall, D.P. Fairlie. 2010. update 1 of: proteases universally recognize beta strands in their active sites. Chem. Rev. 110, 3299.
[25] H. Kase, M. Kaneko, K. Yamada. 1987. K-13, a novel inhibitor of angiotensin I converting enzyme produced by Micromonospora halophytica subsp. exilisia. I. Fermentation, isolation and biological properties. J. Antibiot. (Tokyo) 40, 450.
[26] S. Sano, K. Ikai, K. Katayama, K. Takesako, T. Nakamura, A. Obayashi, Y. Ezure, H. Enomoto. 1986. OF4949, new inhibitors of aminopeptidase B. II. Elucidation of structure. J. Antibiot. (Tokyo) 39, 1685.
[27] J. W. Janetka, P. Raman, K. Satyshur, G. R. Flentke, D. H. Rich. 1997. Novel cyclic biphenyl ether peptide β-strand mimetics and HIV protease inhibitors. J. Am. Chem. Soc. 119, 441.
[28] M. P. Glenn, D. P. Fairlie. 2002. Mimetics of the peptide beta-strand. Mini-Rev. Med. Chem. 2, 433.
[29] Z. Q. Tian, B. B. Brown, D. P. Mack, C. A. Hutton, P. A. Bartlett. 1997. Potentially macrocyclic peptidyl boronic acids as chymotrypsin inhibitors. J. Org. Chem. 62, 514.
[30] D. E. Koshland. 1958. Application of a theory of enzyme specificity to protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 44, 98.
[31] R. C. Reid, L. K. Pattenden, J. D. Tyndall, J. L. Martin, T. Walsh, D. P. Fairlie. 2004. Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. J. Med. Chem. 47, 1641.
[32] L. J. MacPherson, E. K. Bayburt, M. P. Capparelli, R. S. Bohacek, F. H. Clarke, R. D. Ghai, Y. Sakane, C. J. Berry, J. V. Peppard, A. J. Trapani. 1993. Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor. J. Med. Chem. 36, 3821.
[33] H. M. Holden, D. E. Tronrud, A. F. Monzingo, L. H. Weaver, B. W. Matthews. 1987. Slow- and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. Biochemistry 26, 8542.
[34] G. M. Ksander, R. de Jesus, A. Yuan, R.D. Ghai, C. McMartin, R. Bohacek. 1997. Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J. Med. Chem. 40, 506.
[35] G. M Ksander, R. de Jesus, A. Yuan, R. D. Ghai, A. Trapani, C. McMartin, R. Bohacek. 1997. Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J. Med. Chem. 40, 495.
[36] J. W. Janetka, D. H. Rich. 1995. Synthesis of peptidyl ruthenium pi-arene complexes: application to the synthesis of cyclic biphenyl ether peptides. J. Am. Chem. Soc. 117, 10585.
[37] B. L. Podlogar, R. A. Farr, D. Friedrich, C. Tarnus, E. W. Huber, R. J. Cregge, D. Schirlin. 1994. Design, synthesis, and conformational analysis of a novel macrocyclic HIV-protease inhibitor. J. Med. Chem. 37, 3684.
[38] A. L. Swain, M. M. Miller, J. Green, D. H. Rich, J. Schneider, S. B. Kent, A. Wlodawer. 1990. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc. Natl. Acad. Sci. U.S.A. 87, 8805
[39] J. L. Martin, J. Begun, A. Schindeler, W. A. Wickramasinghe, D. Alewood, P. F. Alewood, D. A. Bergman, R. I. Brinkworth, G. Abbenante, D. R. March, R. C. Reid, D. P. Fairlie. 1999. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry 38, 7978.
[40] G. Abbenante, D. A. Bergman, R. I. Brinkworth, D. R. March, R. C. Reid, P. A. Hunt, I. W. James, R. J.

Dancer, B. Garnham, M. L. Stoermer, D. P. Fairlie. 1996. Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 6, 2531.
[41] N. A. Roberts, J. C. Craig, I. B. Duncan. 1992. HIV proteinase inhibitors. Biochem. Soc. Trans. 20, 513.
[42] D. P. Fairlie, J. D. Tyndall, R. C. Reid, A. K. Wong, G. Abbenante, M. J. Scanlon, D. R. March, D. A. Bergman, C. L. Chai, B. A. Burkett. 2000. Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing. J. Med. Chem. 43, 1271.
[43] R. C. Reid, M. J. Kelso, M. J. Scanlon, D. P. Fairlie. 2002. Conformationally constrained macrocycles that mimic tripeptide beta- strands in water and aprotic solvents. J. Am. Chem. Soc. 124, 5673–5683.
[44] J. D. Tyndall, L. K. Pattenden, R. C. Reid, S. H. Hu, D. Alewood, P. F. Alewood, T. Walsh, D. P. Fairlie, J. L. Martin. 2008. Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease. Implications for the catalytic mechanism. Biochemistry 47, 3736.
[45] A. K. Ghosh, L. M. Swanson, H. Cho, S. Leshchenko, K. A. Hussain, S. Kay, D. E. Walters, Y. Koh, H. Mitsuya2005. Structure- based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. J. Med. Chem. 48, 3576–3585.
[46] A. K. Ghosh, S. Kulkarni, D. D. Anderson, L. Hong, A. Baldridge, Y. F. Wang, A. A. Chumanevich, A. Y. Kovalevsky, Y. Tojo, M. Amano, Y. Koh, YJ. Tang, I. T. Weber, I. H. Mitsuya. 2009. Design synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. J. Med. Chem. 52, 7689.
[47] Y. Tojo, Y. Koh, M. Amano, M. Aoki, D. Das, A. K Ghosh, H. Mitsuya. 2010. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis- THF) that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob. Agents Chemother. 54, 3460.
[48] A. K. Ghosh, L. M. Swanson, C. Liu, K. A. Hussain, H. Cho, D. E. Walters, L. Holland, J. Buthod. 2002. Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis-based strategy. Bioorg. Med. Chem. Lett. 12,1993.
[49] A. D. Abell, M. A. Jones, J. M. Coxon, J. D. Morton, S. G. Aitken, S. B. McNabb, H. Y. Lee, J. M. Mehrtens, N. A. Alexander, B. G. Stuart, A. T. Neffe, R. Bickerstaffe. 2009. Molecular modeling, synthesis, and biological evaluation of macrocyclic calpain inhibitors. Angew. Chem., Int. Ed. 48, 1455.
[50] K. Ersmark, M. Nervall, H. Gutierrez-de-Teran, E. Hamelink, L. K. Janka, J. C. Clemente, B. M. Dunn, A. Gogoll, B. Samuelsson, J. Qvist, A. Hallberg. 2006. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg. Med. Chem. 14, 2197.
[51] D. H. Steinman, M. L. Curtin, R. B. Garland, S. K. Davidsen, H. R. Heyman, J. H. Holms, D. H. Albert, T. J. Magoc, I. B. Nagy, P. A. Marcotte, J. Li, D. W. Morgan, C. Hutchins, J. B. Summers. 1998. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. Bioorg. Med. Chem. Lett. 8, 2087.
[52] A. D. Kwong, L. McNair, I. Jacobson, S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8, 522.
[53] S. Di Marco, M. Rizzi, C. Volpari, M. A. Walsh, F. Narjes, S. Colarusso, R. De Francesco, V. G. Matassa, M. Sollazzo. 2000. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 275, 7152.
[54] T. J. Tucker, S. F. Brady, W. C. Lumma, S. D. Lewis, J. Gardell, A. J. Naylor-Olsen. 1998. Med. Chem. 41, 3210.
[55] P. G. Nantermet, J. C. Barrow, C. L. Newton, J. M. Pellicore, M. Young, S. D. Lewis. 2003. Bioorg. Med. Chem. Lett. 13, 2781–2784.
[56] B. E. Maryanoff, X. Qiu, K. P. Padmanabhan, A. Tulinsky, H. R. Almond, P. Andrade-Gordon, M. N. Greco, J. A. Kauffman, K. C. Nicolaou. 1993. Natl. Acad. Sci. U.S.A. 90, 8048.
[57] R. M. Jones, P. D. Boatman, G. Semple, Y. J. Shin, S. Y. Tamura. 2003. Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors. Curr. Opin. Pharma- col. 3, 530.
[58] T. Klabunde, G. Hessler. 2002. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 3, 928.
[59] D. A. Horton, G. T. Bourne, M. L. Smythe. 2002. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Mol. Diversity 5, 289.
[60] E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz. 1992. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. U.S.A. 89, 5286.

[61] E. De Clercq, N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema. 1994. Highly potent and selective inhibition of human immuno- deficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38, 668.
[62] H. C. Joao, K. De Vreese, R. Pauwels, E. De Clercq, G. W. Henson, G. J. Bridger. 1995. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J. Med. Chem. 38, 3865.
[63] A. Steen, T. W. Schwartz, M. M. Rosenkilde. 2009. Targeting CXCR4 in HIV cell-entry inhibition. Mini-Rev. Med. Chem. 9, 1605.
[64] E. De Clercq. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discovery 2, 581.
[65] S. Hatse, K. Princen, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz. 2005. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol. 70 752.
[66] G. J. Bridger, R. T. Skerlj, P. E. Hernandez-Abad, D. E. Bogucki, Z. Wang, Y. Zhou. 2010. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J. Med. Chem. 53, 1250.
[67] E. Marsault, H. R. Hoveyda, M. L. Peterson, C. Saint-Louis, A. Landry, M. Vezina. 2006. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J. Med. Chem. 49, 7190.
[68] E Marsault, K. Benakli, S. Beaubien, C. Saint-Louis, R. Deziel, G. Fraser. 2007. Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids. Bioorg. Med. Chem. Lett. 17, 4187.
[69] G. Fraser, E. Marsault, B. Coolie, L. ver Donck. 2006. Motilin receptor antagonism attenuates naturally occurring MMCs and reverses motilin-impaired gastric accommodation in conscious dogs. Gastroen- terology 130, A31.
[70] A. A. Bogan, K. S. Thorn. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1.
[71] B. Ma, R. Nussinov. 2007. Trp/Met/Phe hot spots in protein- protein interactions: potential targets in drug design. Curr. Top. Med. Chem. 7, 999.
[72] S. S. Yip, A. J. Crew, J. M. Gee, R. Hui, R. W. Blamey, J. F. Robertson, R. I. Nicholson, R. L. Sutherland, R. J. Daly. 2000. Up- regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer 88, 363.
[73] J. Rahuel, B. Gay, D. Erdmann, A. Strauss, C. Garcia-Echeverria, P. Furet, G. Caravatti, H. Fretz, J. Schoepfer, M. G. Grutter. 1996. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat. Struct. Biol. 3, 586.
[74] Y. Gao, J. Voigt, J. X. Wu, D. Yang, T. R. Burke. 2001. Jr. Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. Bioorg. Med. Chem. Lett. 11, 1889.
[75] Z. D Shi, K. Lee, H. Liu, M. Zhang, L. R. Roberts, K. M. Worthy, M. J. Fivash, R. J. Fisher, D. Yang, T. R. Burke. 2003. Jr. A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. Biochem. Biophys. Res. Commun. 310, 378.
[76] Z. D. Shi, C. Q. Wei, K. Lee, H. Liu, M. Zhang, T. Araki, L. R. Roberts, K. Jr Worthy. 2004. Macrocyclization in the design of non- phosphorus-containing Grb2 SH2 domain-binding ligands. J. Med. Chem. 47, 2166.
[77] J. Phan, Z. D. Shi, T. R. Burke, D. S. Waugh. 2005. Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. J. Mol. Biol. 353, 104.
[78] S. Maliartchouk, Y. Feng, L. Ivanisevic, T. Debeir, A. Cuello, K. Burgess, H. U. Saragovi. 2000. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol. Pharmacol. 57, 385.
[79] M. Pattarawarapan, M. C. Zaccaro, U. H. Saragovi, K. Burgess. 2002. New templates for syntheses of ring-fused, C (10) beta-turn peptidomimetics leading to the first reported small-molecule mimic of neurotrophin-3. J. Med. Chem. 45, 4387.
[80] M. C. Zaccaro, H. B. Lee, M. Pattarawarapan, Z. Xia, A. Caron, P. J. L'Heureux, Y. Bengio, K. Burgess, H. U. Saragovi. 2005. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem. Biol. 12, 1015.

Publication History
Received 29.07.2020
Revised 19.08.2020
Accepted 15.09.2020
Online 30.09.2020